NasdaqGS:REGNBiotechs
Regeneron’s EYLEA HD Label Update Shifts Retinal Care And Competition
Regeneron Pharmaceuticals (NasdaqGS:REGN) received FDA approval to extend EYLEA HD dosing intervals for wet age-related macular degeneration and diabetic macular edema up to every 20 weeks.
The decision is based on two year efficacy and safety data and updates the product label to reflect longer potential intervals between injections.
The change may reduce treatment burden for eligible patients and could influence how eye specialists plan long term care for wAMD and DME.
Regeneron enters...